NASDAQ:AKUS Akouos (AKUS) Stock Price, News & Analysis → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free AKUS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$13.29▼$13.2950-Day Range$13.29▼$13.2952-Week Range$2.32▼$13.60Volume440 shsAverage Volume344,411 shsMarket Capitalization$490.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Akouos alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. About Akouos Stock (NASDAQ:AKUS)Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.Read More Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. AKUS Stock News HeadlinesApril 5, 2024 | benzinga.comJoshua Makower's Net WorthMay 17, 2023 | health.usnews.comWilliam W. Backus HospitalApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.May 16, 2023 | finance.yahoo.comRectify Pharmaceuticals Appoints Sachiyo Minegishi as Chief Operating OfficerDecember 1, 2022 | finance.yahoo.comLilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic DiseasesNovember 14, 2022 | finance.yahoo.comAkouos Reports Third Quarter 2022 Financial Results and Provides Business HighlightsOctober 19, 2022 | seekingalpha.comAkouos stock soars 87% as Lilly nabs hearing loss gene therapy developer - Seeking AlphaOctober 18, 2022 | businesswire.comAKUS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akouos, Inc. Is Fair to Shareholders - Business WireApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.October 18, 2022 | benzinga.comCrude Oil Drops Over 2%; Akouos Shares Spike Higher - Akouos (NASDAQ:AKUS), ADS-TEC Energy (NASDAQ:ADSE) - BenzingaOctober 18, 2022 | law360.comEli Lilly To Pay Up To $610M For Gene Therapy Biz Akouos - Law360October 18, 2022 | nasdaq.comEli Lilly to buy genetic medicine developer Akouos for $487 million - NasdaqOctober 18, 2022 | stockhouse.com2022-10-18 | NDAQ:AKUS | Press Release | Akouos Inc. - StockhouseOctober 18, 2022 | marketwatch.comEli Lilly to Buy Akouos for Up to $610 Million >LLY AKUS - MarketWatchOctober 18, 2022 | marketwatch.comAkouos Shares Soar on Takeover by Eli Lilly >AKUS - MarketWatchOctober 18, 2022 | marketwatch.comEli Lilly to acquire Akouos for up to about $610 million and develop gene therapies for hearing loss - MarketWatchOctober 18, 2022 | streetinsider.comEli Lilly & Co. (LLY) Acquires Akouos (AKUS) for $610M - StreetInsider.comOctober 18, 2022 | nasdaq.comEli Lilly To Buy Akouos For Up To $610 Mln - NasdaqOctober 10, 2022 | nasdaq.comAkouos, Inc. (AKUS) Upgraded to Strong Buy: Here's Why - NasdaqOctober 10, 2022 | finance.yahoo.comAkouos, Inc. (AKUS) Upgraded to Strong Buy: Here's WhySeptember 29, 2022 | seekingalpha.comAKUS stock rated Bullish at William Blair on gene therapy for hearing loss (NASDAQ:AKUS) - Seeking AlphaSeptember 29, 2022 | marketscreener.comAkouos Gains as William Blair Starts Coverage at Outperform - Marketscreener.comSeptember 27, 2022 | finance.yahoo.comArthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures - Yahoo FinanceSeptember 14, 2022 | uk.investing.comWhy Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday By Benzinga - Investing.com UKSeptember 14, 2022 | finance.yahoo.comAlcohol Justice to Participate at Alcohol Policy-19 Evidence to Action: Building a Framework for Change - Yahoo FinanceSeptember 13, 2022 | finance.yahoo.comFDA Clears Akouos' Gene Therapy Trial For Genetic Form Of Hearing LossSeptember 13, 2022 | finance.yahoo.comAkouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing LossSee More Headlines Receive AKUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akouos and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AKUS CUSIPN/A CIK1722271 Webwww.akouos.com Phone857-410-1818FaxN/AEmployees103Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-45.09% Return on Assets-36.86% Debt Debt-to-Equity RatioN/A Current Ratio17.30 Quick Ratio17.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.90 per share Price / Book2.71Miscellaneous Outstanding Shares36,936,000Free Float35,163,000Market Cap$490.88 million OptionableNot Optionable Beta-0.55 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Emmanuel Simons M.B.A. (Age 39)Ph.D., Co- Founder, Pres, CEO & Director Comp: $790.72kDr. Michael John McKenna M.D. (Age 65)Co-Founder, Chief Medical Officer & Member of Scientific Advisory Board Comp: $539.35kMs. Jennifer Anne Wellman M.S. (Age 44)Chief Operating Officer Comp: $568.67kDr. Luk H. Vandenberghe M.D.Ph.D., Founder & Member of Scientific Advisory BoardMr. William F. Sewell Ph.D.Founder & Member of Scientific Advisory BoardMr. Richard Smith M.D.Founder & Member of Scientific Advisory BoardMs. Sachiyo Minegishi (Age 44)CFO, Treasurer, Assistant Sec. & Principal Accounting Officer Ms. Stacy PriceChief Technical OfficerDr. Aaron Tward M.D.Ph.D., Chief Scientific OfficerDr. Karoline K. ShairSr. VP, Gen. Counsel, Chief Legal Officer & Corp. Sec.More ExecutivesKey CompetitorsArbutus BiopharmaNASDAQ:ABUSOculisNASDAQ:OCSKalVista PharmaceuticalsNASDAQ:KALVApplied TherapeuticsNASDAQ:APLTCOMPASS PathwaysNASDAQ:CMPSView All Competitors AKUS Stock Analysis - Frequently Asked Questions How were Akouos' earnings last quarter? Akouos, Inc. (NASDAQ:AKUS) announced its earnings results on Friday, November, 12th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.04. What other stocks do shareholders of Akouos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akouos investors own include NVIDIA (NVDA), QUALCOMM (QCOM), RTX (RTX), CVS Health (CVS), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Home Depot (HD), Pfizer (PFE) and Procter & Gamble (PG). When did Akouos IPO? Akouos (AKUS) raised $124 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and BTIG was co-manager. This page (NASDAQ:AKUS) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akouos, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
